11 research outputs found
Annualized rates of HIV infection among male and female VCT clients in Moshi, Tanzania, 2003–2007.
*<p>Rates of HIV infection per 100 person years at risk</p
HIV seropositivity among women and men presenting for VCT, by number of lifetime partners and age of tester in Moshi, Tanzania, 2003–2007.
<p>Among women, subjects between 30 and 39 years old had the highest risk of seropositivity in each category of lifetime sexual partners (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0003075#pone-0003075-g002" target="_blank">Figure 2</a>, Panel A), while subjects 40 years or older had the greatest rise in risk of seropositivity with increasing numbers of sexual partners. The associations were similar but not as strong among men (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0003075#pone-0003075-g002" target="_blank">Figure 2</a>, Panel B). Non-parametric trend tests of associations between the number of partners and seropositivity were significant among men in the youngest and two oldest age groups only (p = 0.016; p = 0.035; and p = 0.001, respectively) and among women showed significant effects in all age groups (p<0.0001 to p = 0.006).</p
Absolute risk of HIV seropositivity among women and men presenting for VCT, by number of lifetime sexual partners in Moshi, Tanzania, 2003–2007, N = 6,531.
<p>Absolute risk of HIV seropositivity among women and men presenting for VCT, by number of lifetime sexual partners in Moshi, Tanzania, 2003–2007, N = 6,531.</p
Correlates of HIV infection by gender among 6,104 clients presenting for VCT in Moshi, Tanzania, 2003–2007.
<p>Odds ratios and [95% confidence intervals] from logistic regression models predicting seropositivity. <sup>*</sup>, <sup>**</sup>, and <sup>***</sup> denote statistical significance at the 0.05, 0.01, and 0.001 levels, respectively. Ref. denotes reference category. Observations with missing covariates were dropped from the analysis. TSH, Tanzania shilling.</p
Treatment failure and risk and incidence of recurrent parasitaemia.
<p>Treatment failure and risk and incidence of recurrent parasitaemia.</p
Cumulative risk of <i>P</i>. <i>vivax</i> recurrence in all four treatment arms over the entire follow-up time.
<p>AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine; CQ+PQ, chloroquine + primaquine.</p
Baseline characteristics of the study population.
<p>Baseline characteristics of the study population.</p
CONSORT flowchart of patient allocation for the day 42 outcome.
<p>AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine; CQ+PQ, chloroquine + primaquine; G6PD, glucose-6-phosphate dehydrogenase; Lost, lost to follow-up.</p
Parasite and fever clearance by treatment arm.
<p>Parasite and fever clearance by treatment arm.</p